CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Ablationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05152966
NCT05152966N/ACompleted
CompareCT.gov

PersAFOne II(Pronounced Per-'Se-fa-nē 2); Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation

Boston Scientific Corporation·interventional·Posted Dec 10, 2021·Updated Feb 28, 2024

In Brief

A clinical study evaluating Ablation for Persistent Atrial Fibrillation. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The objective of this safety and feasibility study is to assess whether the endocardial creation of electrically nonconductive lesions via PEF catheter ablation applied using the FARAPULSE Cardiac Ablation System Plus is a feasible and safe treatment for PersAF and associated AFL

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPersistent Atrial Fibrillation
CountriesCzechia
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedDec 10, 2021
Enrollment StartSep 16, 2021
Primary CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.6 years ago

Interventions

Ablationdevice

Ablation using the FARAPULSE™ Cardiac Ablation System Plus